Fifty-two percent of metastatic lung cancer patients fail to get life-extending treatments, a new study finds.
According to a recent story by Simar Bajaj in The New York Times, the reason they skip such treatments as chemotherapy, immunotherapy. and targeted therapy is, experts suggest, because of "access issues, fatalism, and shame."
The Times article reports that the study, published in JAMA Oncology, "analyzed more than 250,000 people on Medicare between 2006 and 2021, with an average age of 73, and found that the proportion of patients who received these treatments increased only slightly over time, to 48 percent from 45 percent."
More than 110,000 Americans are annually diagnosed with metastatic lung cancer, the deadliest cancer in the United States.
![]() |
| Dr. Carolyn J. Presley |
Some patients who smoked "might feel like they brought this disease upon themselves," Bajaj's story says, and — according to Dr. Adam Fox, pulmonologist at the Medical University of South Carolina, who led the study — the stigma not only contributes to diagnostic delays but also to patients feeling unworthy of care.
Fatalism, the lingering belief that metastatic lung cancer is hopeless and treatment is unlikely to help, might be adopted by some primary care and emergency medicine doctors, the article suggests.
As for access issues, "one of the biggest barriers to treatment is not being diagnosed in time. Screening can catch tumors early, but it remains widely underutilized, largely because most people don't know it's available and complicated eligibility criteria make it difficult for docs to figure out who qualifies," Bajaj's piece notes.

No comments:
Post a Comment